Guard Therapeutics
Guard Therapeutics is developing innovative therapies focusing on kidney diseases. The company's lead clinical asset, RMC-035, is in phase 2b development for the prevention and treatment of kidney injuries in patients undergoing open heart surgery. The company also has preclinical candidate drugs intended for the treatment of chronic kidney disease, targeting specific disease segments such as FSGS, IgAN, Alport Syndrome and DKD. Listed on Nasdaq First North Growth Market.
7-day free trial · no credit card
Verified contacts
8
available on Kipplo
LinkedIn employees
16
1 to 10 range
Open roles
—
no listings
Distinct roles
8
indexed titles
Tech stack
0
tools in use
Monthly traffic
17
organic / mo
Sign up free to see all 8 verified contacts at Guard Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
8 contacts with verified email or phone · masked until revealed.
- TL
Torbjörn Larsson
Head of Cmc · Research & Development
EmailPhone - CS
Camilla Svanström
Qc Manager, Cmc · Other
EmailPhone - KB
Karin Botha
Chief Financial Officer · Finance & Accounting
EmailPhone - MR
Michael Reusch
Ä -, · Other
EmailPhone - TL
Tobias L Agervald
Chief Executive Officer · Other
EmailPhone
Showing 5 of 8 verified contacts
Top roles at Guard Therapeutics
8 distinct titles indexed · top 8 shown.
- 1,,
- 1chief executive officer
- 1chief financial officer
- 1head of cmc
- 1medical director
- 1member board of directors
- 1qc manager, cmc
- 1ä -,
Sign up to unlock all 8 contacts at Guard Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 8 verified contacts at Guard Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.